Navigation Links
Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update
Date:8/14/2008

SOUTH EASTON, Mass., Aug. 14 /PRNewswire-FirstCall/ -- Pressure BioSciences, Inc. (Nasdaq: PBIO) ("PBI" and the "Company") today announced that total revenue for the second quarter of 2008 was $120,184 compared to $202,127 for the comparable period in the prior year. Revenue from the sale of PCT products and services was $117,698 for the three months ended June 30, 2008 as compared to $136,355 for the prior year period. During the second quarter of 2008, we completed the installation of seven Barocycler instruments at customer locations, as compared to four in the same period of 2007. This decrease in revenue, despite an increase in the number of installations, was primarily due to a shift in the type of instrument installed: three of the seven installations in the second quarter of 2008 were the less expensive NEP2320, whereas all four installations in the second quarter of 2007 were the more expensive NEP3229. Also contributing to the decrease in revenue, despite an increase in the number of installations, was the fact that two of our seven installations in the second quarter of 2008 were completed under short-term rental agreements. These agreements have a minimal impact on current period revenue but provide a revenue stream over the course of the respective agreements in the form of monthly rental payments and purchases of our consumable products.

Edward H. Myles, Senior Vice President of Finance and CFO, said: "Although the seven installations of Pressure Cycling Technology ("PCT") Sample Preparation Systems ("PCT Systems") in the second quarter of 2008 were significantly higher than the four PCT Systems installed in the same period in 2007, we had hoped to have installed more. That being said, we are very encouraged by the fa
'/>"/>

SOURCE Pressure BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Pressure BioSciences, Inc. to Discuss Second Quarter 2008 Financial Results and Provide Business Update
2. Pressure BioSciences, Inc. Announces the Market Release of its PCT-Enhanced Trypsin Digestion Application for Proteomics
3. Healthcare Industry Faces Mounting Pressure to Prevent On-The-Job Violence, Says Veteran Safety and Health Attorney
4. RADI Medical Systems Launches Next Generation PressureWire(R) Certus
5. Four Independent Research Groups Present Data Generated by Pressure Cycling Technology (PCT) at the ASMS Conference on Mass Spectrometry and Allied Topics in Denver, CO
6. InterCure Supports AHA Endorsement of Home Blood Pressure Monitoring
7. International Wound Care Experts, Medline Announce Pressure Ulcer Prevention Consensus Paper
8. Pressure BioSciences, Inc. to Discuss First Quarter 2008 Financial Results and Provide Business Update
9. Significant Reductions in Mortality and Cardiovascular Events Shown Using Blood Pressure-Lowering Treatment in Those Aged 80 and Over
10. Matthew B. Potter Joins Pressure BioSciences, Inc. as Vice President of Sales
11. Pressure BioSciences, Inc. to Discuss 2007 Financial Results and Provide Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 2ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 3ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 4AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 3Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 2Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 3